Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Adjuvants, Immunologic
/ administration & dosage
Animals
CD8-Positive T-Lymphocytes
/ immunology
Cancer Vaccines
/ administration & dosage
Cell Line, Tumor
Cytokines
/ metabolism
Drug Delivery Systems
Female
Humans
Immunotherapy
/ methods
Liposomes
/ administration & dosage
Mannose
/ chemistry
Mice, Inbred C57BL
Oligodeoxyribonucleotides
/ administration & dosage
Papillomavirus E7 Proteins
/ administration & dosage
Papillomavirus Vaccines
/ administration & dosage
T-Lymphocytes, Cytotoxic
/ drug effects
Tumor Microenvironment
/ drug effects
Xenograft Model Antitumor Assays
CpG ODN adjuvant
human papillomavirus
immunotherapy
liposome
peptide vaccine
tumor microenvironment
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
08
2020
accepted:
10
11
2020
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
9
1
2021
Statut:
epublish
Résumé
Previously, we demonstrated the therapeutic efficacy of a human papillomavirus (HPV) vaccine, including HPV16 E7 peptide and CpG oligodeoxynucleotides (CpG ODN), against small TC-1 grafted tumors. Here, we developed an HPV16 E7 peptide and CpG ODN vaccine delivered using liposomes modified with DC-targeting mannose, Lip E7/CpG, and determined its anti-tumor effects and influence on systemic immune responses and the tumor microenvironment (TME) in a mouse large TC-1 grafted tumor model. L-alpha-phosphatidyl choline (SPC), cholesterol (CHOL), 1,2-distearoyl- Lip E7/CpG had a diameter of 122.21±8.37 nm and remained stable at 4°C for 7 days. Co-delivery of HPV16 E7 peptide and CpG ODN by liposomes exerted potent anti-tumor effects in large (tumor volume ≥200mm Lip E7/CpG induced anti-tumor effects by enhancing cellular immunity and improving tumor-associated immunosuppression. Mannose-modified liposomes are the promising vaccine delivery strategy for cancer immunotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Previously, we demonstrated the therapeutic efficacy of a human papillomavirus (HPV) vaccine, including HPV16 E7 peptide and CpG oligodeoxynucleotides (CpG ODN), against small TC-1 grafted tumors. Here, we developed an HPV16 E7 peptide and CpG ODN vaccine delivered using liposomes modified with DC-targeting mannose, Lip E7/CpG, and determined its anti-tumor effects and influence on systemic immune responses and the tumor microenvironment (TME) in a mouse large TC-1 grafted tumor model.
METHODS
METHODS
L-alpha-phosphatidyl choline (SPC), cholesterol (CHOL), 1,2-distearoyl-
RESULTS
RESULTS
Lip E7/CpG had a diameter of 122.21±8.37 nm and remained stable at 4°C for 7 days. Co-delivery of HPV16 E7 peptide and CpG ODN by liposomes exerted potent anti-tumor effects in large (tumor volume ≥200mm
CONCLUSION
CONCLUSIONS
Lip E7/CpG induced anti-tumor effects by enhancing cellular immunity and improving tumor-associated immunosuppression. Mannose-modified liposomes are the promising vaccine delivery strategy for cancer immunotherapy.
Identifiants
pubmed: 33293808
doi: 10.2147/IJN.S275670
pii: 275670
pmc: PMC7718974
doi:
Substances chimiques
Adjuvants, Immunologic
0
CPG-oligonucleotide
0
Cancer Vaccines
0
Cytokines
0
Liposomes
0
Oligodeoxyribonucleotides
0
Papillomavirus E7 Proteins
0
Papillomavirus Vaccines
0
oncogene protein E7, Human papillomavirus type 16
0
Mannose
PHA4727WTP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9571-9586Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 Zhao et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Nature. 2010 Jan 21;463(7279):369-73
pubmed: 20090753
PLoS One. 2013 May 10;8(5):e63078
pubmed: 23675454
J Immunol. 2002 Feb 1;168(3):1212-8
pubmed: 11801657
Recent Pat Inflamm Allergy Drug Discov. 2015;9(1):38-45
pubmed: 25642777
ISRN Oncol. 2013;2013:753427
pubmed: 23533812
Springer Semin Immunopathol. 1999;21(3):339-59
pubmed: 10666777
Pharm Res. 2014 Oct;31(10):2563-82
pubmed: 24848341
Cell. 2001 Aug 10;106(3):255-8
pubmed: 11509172
Int J Gynecol Cancer. 2019 Oct;29(8):1317-1326
pubmed: 31455660
Oncoimmunology. 2013 Aug 1;2(8):e25961
pubmed: 24083084
Front Immunol. 2012 Mar 21;3:51
pubmed: 22566933
J Clin Invest. 2015 Sep;125(9):3356-64
pubmed: 26168215
Expert Rev Clin Immunol. 2017 Nov;13(11):1049-1060
pubmed: 28965431
Nature. 2001 May 17;411(6835):375-9
pubmed: 11357145
Nat Rev Immunol. 2012 Jul 13;12(8):557-69
pubmed: 22790179
Nat Rev Immunol. 2007 Oct;7(10):790-802
pubmed: 17853902
Cell. 2000 Mar 3;100(5):575-85
pubmed: 10721994
Int Immunopharmacol. 2019 Apr;69:279-288
pubmed: 30743204
J Immunol. 2007 May 15;178(10):6259-67
pubmed: 17475854
Oncoimmunology. 2014 Nov 14;3(8):e953407
pubmed: 25960932
Hum Vaccin Immunother. 2014;10(11):3175-8
pubmed: 25483658
J Control Release. 2013 Nov 28;172(1):259-265
pubmed: 24004885
Discov Med. 2012 Aug;14(75):125-31
pubmed: 22935209
J Immunol. 1998 Jul 15;161(2):927-32
pubmed: 9670971
Hum Vaccin Immunother. 2020;16(2):426-435
pubmed: 31448991
Expert Rev Vaccines. 2011 Apr;10(4):513-21
pubmed: 21506648
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:59-72
pubmed: 29108943
J Exp Med. 1998 Oct 5;188(7):1359-68
pubmed: 9763615
J Exp Med. 2004 Mar 15;199(6):815-24
pubmed: 15024047
Rev Physiol Biochem Pharmacol. 2018;175:47-69
pubmed: 29700609
Cancer Res. 2004 Jun 15;64(12):4357-65
pubmed: 15205352
Arch Immunol Ther Exp (Warsz). 2018 Apr;66(2):97-111
pubmed: 28660349
Vaccine. 2009 Jan 14;27(3):378-87
pubmed: 19022317
DNA Cell Biol. 2014 May;33(5):282-90
pubmed: 24548334
Expert Opin Biol Ther. 2004 Dec;4(12):1953-62
pubmed: 15571457
Cancer Immunol Immunother. 2020 Dec;69(12):2651-2664
pubmed: 32607768
Cytotechnology. 2016 Dec;68(6):2223-2233
pubmed: 27193424
Annu Rev Immunol. 2012;30:1-22
pubmed: 22136168
J Clin Oncol. 2015 May 10;33(14):1543-50
pubmed: 25823737
Virchows Arch. 2005 Jun;446(6):626-33
pubmed: 15891905
Biomaterials. 2015 Nov;68:54-66
pubmed: 26264646
J Cell Biol. 2000 Oct 30;151(3):673-84
pubmed: 11062267
Front Pharmacol. 2018 Sep 05;9:980
pubmed: 30233368